AxoGen, Inc.’s Avance® Nerve Graft Data to be Presented at 2016 Federation of European Societies for Surgery of the Hand International Congress
ALACHUA, Fla., June 21, 2016 (GLOBE NEWSWIRE) — AxoGen, Inc. (AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the acceptance of four presentations at the Congress of the Federation of European Societies for Surgery of the Hand (FESSH) related to use of Avance® Nerve Graft, including data from the RANGER® Registry. The data to be presented highlights that sensory and motor recovery outcomes from Avance® Nerve Graft repairs, in this group of patients, were found to compare favorably with autograft (nerve transplanted from the patient’s own body). The data contained mixed nerve injuries up to 70 mm repaired with either Avance® Nerve Graft or autograft and both reported outcomes with greater than 85% meaningful recovery.
In addition to these scientific presentations, the FESSH congress, held June 22-25, 2016 at the Santander Exhibition Center in Santander, Spain, will feature two peripheral nerve repair pre-courses, a panel discussion on peripheral nerve repair and AxoGen’s full portfolio of nerve repair products at FESSH Booth 8.
“We are pleased to see the presentation of clinical and scientific data at this year’s FESSH conference supporting the role of Avance® Nerve Graft as a repair alternative for major nerve repairs,” stated Karen Zaderej, AxoGen’s President and Chief Executive Officer. “We believe surgeons gain confidence in our new technologies and convert their surgical decisions with increasing awareness of data and thoughtful peer-to-peer discussions. These initiatives reinforce AxoGen’s position as the preeminent choice for peripheral nerve repair surgery.”
The presentation details for the FESSH conference are as follows:
Tuesday, June 21, 2016
AxoGen Sponsored Pre-Course: Multidisciplinary Peripheral Nerve Disorders. Directors and Lecturers: Joaquim Casañas, Manuel Llusa, Victor Mayoral, A. Isabel Fernandez Conejero, A. Turon, Ivan Ducic, Jordi Serra, Gregory Buncke
Wednesday, June 22, 2016
AxoGen Sponsored Pre-Course: Advances & Best Practices In Upper Extremity Nerve Repair. Faculty: Gregory Buncke, MD, The Buncke Clinic; Joaquim Casañas, MD, Centro Médico Teknon; Ivan Ducic MD, PhD, Nerve and Headache Institute; Bauback Safa MD, MBA, The Buncke Clinic; and Peter Evans, MD, PhD, FRCSC, Cleveland Clinic.
Thursday, June 23, 2016
AxoGen Panel Discussion: Advances in Nerve Repair & Regeneration. Faculty: Joaquim Casañas, MD, Centro Médico Teknon; Bauback Safa MD, MBA, The Buncke Clinic; Peter Evans, MD, PhD, FRCSC, Cleveland Clinic, and Erick DeVinney, AxoGen.
Scientific presentation: A-0590 Comparison of Outcomes from Mixed Nerve Reconstructions in the Upper Extremity with Processed Nerve Allografts and Nerve Autograft from a National Registry Study. Authors: Bauback Safa, MD, MBA, Jason Ko, MD, Harry Hoyen, MD, Wesley Thayer, MD, Gregory Buncke, MD; The Buncke Clinic, San Francisco, USA; University of Washington, Seattle, USA; MetroHealth System, Cleveland, USA; Vanderbilt University Medical Center, Nashville, USA
Scientific presentation: A-0592 Characterization of Processed Human Nerve Allograft with an Organotypic Neurite Outgrowth Measurement. Authors: Jennifer Faleris, Erick DeVinney, Curt Deister, PhD; AxoGen
Scientific presentation: A-0594 Outcome Assessment by Gap Length of Digital Nerve Gap Reconstructions with Processed Nerve Allografts and Manufactured Tube Conduits from a National Registry Study. Authors: Bauback Safa, MD, MBA, Jason Ko, MD, Harry Hoyen, MD, Wesley Thayer, MD, Gregory Buncke, MD; The Buncke Clinic, San Francisco, USA; University of Washington, Seattle, USA; MetroHealth System, Cleveland, USA; Vanderbilt University Medical Center, Nashville, USA
Scientific presentation: A-0641 Novel Methodology for Automated Quantification and Assessment of Bioactive Laminin Endoneurial Tube Scaffolding in Peripheral Nerve Repair Implants.
Authors: Erick DeVinney, Jennifer Faleris, Curt Deister, PhD; AxoGen
About the RANGER® Study
The RANGER® Study, A Multicenter Retrospective Study of Avance® Nerve Graft Utilization Evaluations and Outcomes in Peripheral Nerve Injury Repair is an active, multicenter clinical database with 18 contributing centers designed to continuously monitor and collect injury, repair, safety and outcomes data for peripheral nerve injuries repaired with processed nerve allograft (Avance® Nerve Graft), nerve autograft and synthetic tubes. As of May 2016, the study included more than 850 nerve repairs enrolled across 18 centers and 48 surgeons. The RANGER® Study is an AxoGen sponsored ongoing open label registry study. Each patient outcome is dependent upon the nature and extent of nerve loss or damage, timing between nerve loss and repair and the natural course of the patient’s recovery. Results presented at the FESSH meeting may not represent typical clinical outcomes for individual patients.
